© All rights reserved to Barnea Jaffa Lande Law offices

Regulation

The regulatory burden has intensified in Israel in recent years. In certain fields, the level of regulation in Israel is higher even than in much of the developed world.

This regulation applies to almost every business area our customers operate in: competition and antitrust, banking, capital markets, communications, privacy, life sciences and pharma, environment, infrastructure and energy, and more. Legislative developments in these areas, together with increasing criminal and administrative enforcement in cases of regulatory violations and a growth in private enforcement, require corporations and their managers to be familiar with the regulation in their fields and to consider regulatory issues when making business decisions.

 

Our regulatory team provides solutions to corporations working in a variety of areas including antitrust, banking, capital market, financial services and payment solutions, telecom and media, privacy, food, health, agriculture, environmental protection, business licensing, infrastructure and energy, and more.

 

Our firm offers both knowledge and experience in providing opinions on regulatory issues, advising on licensing and certification processes, and guiding during transactions and entry into activity in Israel. In addition, we represent clients before various regulatory authorities, including the Capital Market Commissioner; the Israel Securities Authority; the Tel Aviv Stock Exchange; the Antitrust Authority; the Second Authority for Television and Radio; the Council for Cable TV and Satellite Broadcasting; the Israeli Law, Information and Technology Authority; the Israeli Dairy Board; and the Center for Local Government, as well as before various government ministries, Knesset committees, and more.

 

Regulation often serves as a barrier to foreign companies looking to operate in Israel. Thanks to our international reputation as a leading israeli law firm, we have become the address for foreign companies seeking both different opinions on their current activities in Israel and accompaniment in all the various regulatory issues with which they must contend.

News and updates - Regulation:


December 5, 2021

Israeli Ministry of Environmental Protection: ILS 3 Million Sanction on Shufersal

The Israeli Ministry of Environmental Protection announced this week its imposition of a pecuniary sanction totaling about ILS 3 million on the leading supermarket chain Shufersal for violations of the Clean Air Law. (In particular, the company violated provisions mandating the reduction and prevention of air pollution from its vehicles).

December 1, 2021

ESG – Risks and Legal Responsibility – A Lecture by Dr. Zvi Gabbay

Since the COVID-19 outbreak and the exacerbation of the climate crisis, ESG factors have increasingly influenced the profit line of businesses. The ESG Management Program at the Coller School of Management at Tel Aviv University, which will open in March 2022, will bring the most important aspects of ESG to those whose activities have an impact on the investment chain: executives, directors, investors, analysts, and public sector personnel.

 

As part of the program, Dr. Zvi Gabbay will give a lecture entitled: "Risks and Legal Responsibility - How ESG Becomes a Significant Part of the Duties of an Organization's Officers and What Happens When Neglected."

November 28, 2021

For the First Time, Israel Competition Authority Enforces Prohibition on Excessive Pricing

For the first time, the Israel Competition Authority has opened enforcement proceedings against a monopolist for abuse of its dominant position by charging an unfairly high price. Subject to a hearing, the authority intends to impose a pecuniary sanction of ILS 8 million on MBI Pharma Ltd. and personal sanctions on two officers of the company (of about ILS 600,000 each). The company faces accusations of charging an excessive price for Leadiant, a life-saving drug for CTX patients (an incurable genetic disease), which is marketed by MBI Pharma in Israel.

Regulation

The regulatory burden has intensified in Israel in recent years. In certain fields, the level of regulation in Israel is higher even than in much of the developed world.

This regulation applies to almost every business area our customers operate in: competition and antitrust, banking, capital markets, communications, privacy, life sciences and pharma, environment, infrastructure and energy, and more. Legislative developments in these areas, together with increasing criminal and administrative enforcement in cases of regulatory violations and a growth in private enforcement, require corporations and their managers to be familiar with the regulation in their fields and to consider regulatory issues when making business decisions.

 

Our regulatory team provides solutions to corporations working in a variety of areas including antitrust, banking, capital market, financial services and payment solutions, telecom and media, privacy, food, health, agriculture, environmental protection, business licensing, infrastructure and energy, and more.

 

Our firm offers both knowledge and experience in providing opinions on regulatory issues, advising on licensing and certification processes, and guiding during transactions and entry into activity in Israel. In addition, we represent clients before various regulatory authorities, including the Capital Market Commissioner; the Israel Securities Authority; the Tel Aviv Stock Exchange; the Antitrust Authority; the Second Authority for Television and Radio; the Council for Cable TV and Satellite Broadcasting; the Israeli Law, Information and Technology Authority; the Israeli Dairy Board; and the Center for Local Government, as well as before various government ministries, Knesset committees, and more.

 

Regulation often serves as a barrier to foreign companies looking to operate in Israel. Thanks to our international reputation as a leading israeli law firm, we have become the address for foreign companies seeking both different opinions on their current activities in Israel and accompaniment in all the various regulatory issues with which they must contend.

P. Banking & Finance, Capital Markets, FinTech, Regulation

P. Banking & Finance, Competition Law and Antitrust, Internet, Regulation, Telecom & Media

News and updates - Regulation:


December 5, 2021

Israeli Ministry of Environmental Protection: ILS 3 Million Sanction on Shufersal

The Israeli Ministry of Environmental Protection announced this week its imposition of a pecuniary sanction totaling about ILS 3 million on the leading supermarket chain Shufersal for violations of the Clean Air Law. (In particular, the company violated provisions mandating the reduction and prevention of air pollution from its vehicles).

December 1, 2021

ESG – Risks and Legal Responsibility – A Lecture by Dr. Zvi Gabbay

Since the COVID-19 outbreak and the exacerbation of the climate crisis, ESG factors have increasingly influenced the profit line of businesses. The ESG Management Program at the Coller School of Management at Tel Aviv University, which will open in March 2022, will bring the most important aspects of ESG to those whose activities have an impact on the investment chain: executives, directors, investors, analysts, and public sector personnel.

 

As part of the program, Dr. Zvi Gabbay will give a lecture entitled: "Risks and Legal Responsibility - How ESG Becomes a Significant Part of the Duties of an Organization's Officers and What Happens When Neglected."

November 28, 2021

For the First Time, Israel Competition Authority Enforces Prohibition on Excessive Pricing

For the first time, the Israel Competition Authority has opened enforcement proceedings against a monopolist for abuse of its dominant position by charging an unfairly high price. Subject to a hearing, the authority intends to impose a pecuniary sanction of ILS 8 million on MBI Pharma Ltd. and personal sanctions on two officers of the company (of about ILS 600,000 each). The company faces accusations of charging an excessive price for Leadiant, a life-saving drug for CTX patients (an incurable genetic disease), which is marketed by MBI Pharma in Israel.

Enter your email for newsletter sign up: